XENE NASDAQ
Xenon Pharmaceuticals Inc.
1W: +2.9%
1M: -36.8%
3M: -37.2%
YTD: -14.5%
1Y: -2.8%
3Y: +8.3%
5Y: +152.3%
$38.02
-0.91 (-2.34%)
Weekly Expected Move ±16.1%
$26
$32
$38
$44
$50
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships5
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2021-12-01
Earliest Filing
2023-11-30
Latest Filing
partner: 5
Counterparties (Filed by XENE)
5 relationshipsCompanies named in XENE's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Jefferies LLC | JEF | partner | Underwriter acting as representative in the public offering of common shares and pre-funded warrants. | 2023-11-30 | View |
| Stifel, Nicolaus & Company, Incorporated | — | partner | Underwriter acting as representative in the public offering of common shares and pre-funded warrants. | 2023-11-30 | View |
| RBC Capital Markets, LLC | — | partner | Underwriter acting as representative in the public offering of common shares and pre-funded warrants. | 2023-11-30 | View |
| Neurocrine Biosciences | NBIX | partner | Collaboration to develop treatments for epilepsy, including exclusive license of NBI-921352. | 2023-08-09 | View |
| Redstone Enterprises Ltd. | — | partner | Landlord in a lease agreement for office and laboratory space. | 2021-12-01 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-06 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-06-03 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-04-13 | Officer/Director Change; Exhibits | View | |
| 2026-03-13 | Other Events; Financial Statements and Exhibits | View | |
| 2026-03-12 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2026-03-09 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-02-27 | Other Events; Financial Statements and Exhibits | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-12-01 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-11-03 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-10-17 | Departure/Election of Directors; Appointment of Officers; Other Events; Financial Statements and Exh | View | |
| 2025-10-16 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-08-11 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-07-03 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-06-05 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-05-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-03-17 | Other Events; Financial Statements and Exhibits | View | |
| 2025-03-05 | Changes in Registrant's Certifying Accountant; Financial Statements and Exhibits | View | |
| 2025-02-27 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-01-17 | Departure/Election of Directors; Appointment of Officers | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR